New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
6th Annual OneMedForum 2013 is being held in San Francisco on January 7-9.
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
06:59 EDTSYNSynthetic Biologics names Steven Shallcross as CFO
Subscribe for More Information
May 1, 2015
16:55 EDTAGENAgenus files to sell 574,140 shares of common stock for holders
Subscribe for More Information
April 29, 2015
10:28 EDTATOSAtossa Genetics management to meet with Roth Capital
Subscribe for More Information
07:08 EDTCLRXCollabRx receives notice from NASDAQ on change of control
Subscribe for More Information
April 28, 2015
07:39 EDTBONEBacterin receives coverage from MAC for hMatrix
Bacterin International Holdings announced that its Acellular Dermal Matrix allograft, hMatrix, has received coverage from Novitas Solutions, a Medicare Administrative Contractor, or "MAC". Novitas is one of eight MACs that are responsible for processing Medicare claims in one or more of twelve geographic areas, or "jurisdictions," in the United States. In addition to processing claims, each MAC is also responsible for issuing local coverage determinations that specify which health care products and services are reimbursable through the Medicare Fee-for-Service program in the regions under its jurisdiction.
April 27, 2015
08:46 EDTAGENAgenus data positive, says JMP Securities
Subscribe for More Information
07:00 EDTSYNSynthetic Biologics reports posters highlight preclinical data from SYN-005
Synthetic Biologics announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015. The "Antibody Cocktail Effectively Treats Pertussis in a Baboon Disease Model" poster summarized preclinical efficacy data that support advancing Synthetic Biologics' novel monoclonal antibody combination, SYN-005, toward the clinic. The poster presented key data from both murine and non-human primate models with the following conclusions: In the murine model, prophylactic administration of hu1B7 and hu11E6, both individually and in combination, completely blocked the rise in white blood cell count that is characteristic of the disease and reduced bacterial colonization in the lungs. In the non-human primate model, therapeutic administration of SYN-005 reversed the rise in white blood cell count and accelerated the clearance of pertussis bacteria. The second poster, entitled "Spontaneous Identification of Bordetella bronchiseptica in a Baboon Colony: Potential Ramifications for Bordetella pertussis Modeling" presented data that further evaluated 16 non-human primates and provided new information important to the future use of this model.
April 24, 2015
09:20 EDTCTSOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
08:03 EDTCTSOCytoSorbents CEO comments on CytoSorb in letter to shareholders
In the letter, CEO Phillip Chan commented, "A significant new opportunity has emerged that may accelerate U.S. approval of CytoSorb for critical illnesses such as sepsis. The FDA has recently issued new guidance on two related topics: the Expedited Access Pathway program and the Balancing of Pre-market and Post-market Data Collection for Devices Subject to Premarket Approval. Together, the EAP and Data Collection programs are designed to facilitate and expedite the U.S. approval of medical devices that treat life-threatening or irreversibly debilitating conditions that have no approved alternative treatments. Similar to "Breakthrough Therapy Designation" for drugs and biologics, devices that achieve EAP Designation would be eligible for more intensive FDA guidance and collaboration with senior managers, and priority review. Meanwhile, the FDA and Device Sponsor would work together to specify the clinical trial design and "least burdensome" efficacy and safety data needed for early marketing approval, leaving the proof of more stringent efficacy to the post-market period. The end result is that devices that are safe and achieve EAP Designation have an opportunity to get to U.S. approval and commercialization much faster, and with less regulatory risk. We believe this new program could benefit CytoSorbents as CytoSorb currently targets the treatment of many life-threatening conditions such as sepsis, acute respiratory distress syndrome, severe acute pancreatitis, trauma, and many others that do not have effective treatments. As we move forward with our REFRESH cardiac surgery trial in the U.S., we plan to aggressively pursue this EAP opportunity for critical care applications in parallel, and foster open collaboration with the FDA."
07:11 EDTAGENAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
April 23, 2015
07:03 EDTAGENAgenus reports Q1 EPS (28c), may not compare to consensus (1c)
Reports Q1 revenue $3.95M, may not compare to consensus $11.66M.
April 22, 2015
14:56 EDTAGENAgenus management to meet with William Blair
Meeting to be held in Philadelphia on April 27 hosted by William Blair.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use